Cost-Effectiveness Analysis of Docetaxel Versus Weekly Paclitaxel in Adjuvant Treatment of Regional Breast Cancer in New Zealand
Rachel Webber-Foster, Giorgi Kvizhinadze, Gareth Rivalland, Tony Blakely
PharmacoEconomics | ADIS INT LTD | Published : 2014
Awarded by Health Research Council of New Zealand
The BODE<SUP>3</SUP> programme receives funding support from the Health Research Council of New Zealand (10/248).